#USA #New York #Levi & Korsinsky #stock investigation #Agios Pharmaceuticals

Investigation Launched for Agios Pharmaceuticals Shareholders

The legal firm Levi & Korsinsky has officially announced the commencement of an investigation focused on Agios Pharmaceuticals, Inc., known for trading under the ticker NASDAQ: AGIO. The investigation arises in the wake of alarming news regarding the company's performance following the results from their Phase 3 clinical trial of their drug, Mitapivat, intended for treating Sickle Cell Disease.

On November 19, 2025, Agios reported mixed outcomes from the RISE UP trial. While the trial successfully met one of its primary endpoints, it failed to achieve significant results in another key area, particularly in demonstrating a substantial improvement in the frequency of pain crises, described as annualized rates of pain. In a disappointing turn, a secondary endpoint, which involved changes in key patient-reported fatigue levels, was also not met, leading to widespread concern among investors.

Consequentially, the stock price of Agios plummeted sharply by $22.33, leading to an opening price of just $23.16 per share in the following trading session. This drastic decline raised questions regarding potential violations of federal securities laws, prompting the legal team's intervention to protect shareholders’ rights.

Legal Action Encouraged

Levi & Korsinsky is reaching out to investors who experienced losses due to the significant drop in Agios' stock value to discuss their possible involvement in this investigation. The firm has a history of representing shareholders in complex legal matters and has collectively secured hundreds of millions of dollars in settlements over the last two decades. As part of their ongoing efforts, they encourage investors who believe they have been wronged to step forward for further assistance.

For more information, concerned shareholders are encouraged to fill out a submission form available through Levi & Korsinsky's website or contact the firm directly via phone or email.

Why Levi & Korsinsky?

With over 20 years of experience in the domain, the firm has cultivated a strong reputation in the field of securities litigation. They have consistently ranked in the Top 50 Report by ISS Securities Class Action Services, highlighting their capacity to navigate high-stakes legal environments successfully. The firm comprises a well-resourced team of over 70 professionals dedicated to safeguarding investors’ interests.

If you have lost money as a result of your investments in Agios Pharmaceuticals, now is the time to act. By joining forces with Levi & Korsinsky, you can ensure that your voice is heard. Schedule a consultation today to explore your options and take proactive steps to recover your investment losses.

Conclusion

The recent investigation into Agios Pharmaceuticals illustrates the potential vulnerabilities that investors face in the pharmaceutical sector, especially in light of mixed trial outcomes and regulatory expectations. As such, it serves as a critical reminder to stakeholders about the value of vigilance and the importance of seeking legal counsel when faced with significant losses. For Agios shareholders, the unfolding situation presents both a challenge and an opportunity for redress, and Levi & Korsinsky stands ready to assist those seeking justice.